FY2025 EPS Estimates for STOK Lifted by Cantor Fitzgerald

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings per share of $0.03 for the year, up from their prior forecast of ($2.40). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Several other research analysts also recently commented on STOK. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. HC Wainwright restated a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $7.74 on Monday. The company has a market capitalization of $418.56 million, a PE ratio of -3.69 and a beta of 0.99. The company has a 50 day moving average price of $9.44 and a 200-day moving average price of $11.30. Stoke Therapeutics has a fifty-two week low of $7.22 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. Bank of New York Mellon Corp lifted its holdings in shares of Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after purchasing an additional 1,330 shares during the period. Graham Capital Management L.P. raised its holdings in shares of Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock valued at $206,000 after acquiring an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after purchasing an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after acquiring an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after buying an additional 2,787 shares during the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.